Vanda Pharmaceuticals has settled its patent dispute with MSN Pharmaceuticals over MSN’s proposed generic version of HETLIOZ LQ, Vanda’s tasimelteon oral suspension. The agreement gives MSN a license to sell its generic in the United States, with market entry generally scheduled for the first quarter of 2040 but possible earlier under specified conditions.
The deal resolves the litigation over MSN’s application to sell the product and sets out limited steps MSN may take before its licensed launch.
Key details
-
License and timing: Vanda granted MSN a non-exclusive, royalty-free license to make, import and market generic tasimelteon suspension in the United States starting in the first quarter of 2040. The agreement does not specify a particular launch date within that quarter.
-
Potential earlier entry: MSN may be able to launch sooner if the licensed patents expire or a final court decision finds them invalid, unenforceable or not infringed. Earlier entry is also possible if Vanda launches an authorized or licensed generic, or if a third-party generic enters and Vanda does not stop it within a specified period.
-
Drug-shortage exception: MSN may supply its product before the license date if the FDA declares a shortage after Vanda voluntarily withdraws HETLIOZ LQ for reasons unrelated to safety or efficacy.
-
Pre-launch activities: MSN may manufacture and import the product starting 180 days before the license date. It may begin customer discussions 30 days beforehand and pricing and contracting discussions 14 days beforehand.
-
Terms tied to future deals: If Vanda later gives another party certain more favorable terms, including on market-entry timing or pre-launch rights, MSN is entitled to those terms as well.
-
Litigation and patent provisions: The parties agreed to end their claims in court. MSN acknowledged the validity and enforceability of the patents at issue as they apply to its product and agreed not to challenge those patents, subject to exceptions. The parties also plan to seek court approval of an injunction barring MSN from selling or otherwise commercializing its generic outside the license.
-
Regulatory review: Vanda and MSN will submit the agreement to the Federal Trade Commission and the Department of Justice for review.
What changes
The settlement ends the patent fight and gives MSN a defined path to sell its generic, while generally delaying licensed entry until 2040. It does not establish an immediate generic launch; earlier entry depends on the circumstances specified in the agreement.
